Biotech Forum: Impact of Globalization in Healthcare

The August Biotech Forum is co-hosted by NC Chinese Business Association (NCCBA – and the Council for Entrepreneurial Development (CED –, with support from NCBIO and the North Carolina Biotechnology Center.

Date: August 15, 2006
Time: 6:30-9 pm (6-6:30 on-site registration)
Location: North Carolina Biotechnology Center, (15 T.W. Alexander Drive, RTP, NC 27709)
Fees: $10 pre-registration online; $15 on-site

Global healthcare systems today are growing at an unsustainable rate while consumers on a worldwide basis are demanding more and better healthcare services. Integration and access to information, innovation and entrepreneurship will play a growing role in aligning escalating demand with discovery and delivery of affordable, quality healthcare.

Multinationals, western private equity funds and large companies have earmarked billions of dollars to invest in global ventures to build financial services, biotech, healthcare and technology industries around the world.

At the August 15th Biotech Forum, join industry thought leaders from diverse perspectives to listen and discuss how globalization and innovation is changing the healthcare (and life sciences) industry, and how we can benefit from such globalization now.

Confirmed Panelists:

* Victor Dzau, MD, Chancellor for Health Affairs, Duke University; President and CEO, Duke University Health System
* Art Pappas, Managing Partner, Pappas Ventures
* Dan Pelino, General Manager, IBM Healthcare and Life Sciences Industry
* John Ratliff, Executive Vice President and Chief Financial Officer, Quintiles Transnational Corp.

Biotech Forum Reception Sponsor:

* IBM Healthcare and Life Sciences

Speaker Biographies:

Victor Dzau, MD, Chancellor for Health Affairs, Duke University; President and CEO, Duke University Health System

* Victor J. Dzau, MD, was appointed Chancellor for Health Affairs at Duke University and President and CEO of the Duke University Health System effective July 1, 2004. He is also James B. Duke Professor of Medicine and Director of Molecular and Genomic Vascular Biology at Duke. Most recently, Dr. Dzau was the Hersey Professor of the Theory and Practice of Physic (Medicine) at Harvard Medical School, Chairman of the Department of Medicine at Brigham and Women's Hospital, and Physician-in-Chief and Director of Research at Brigham and Women's Hospital, Boston. Prior to his work at Harvard and Brigham and Women's, he served as Arthur Bloomfield Professor and Chairman of the Department of Medicine at Stanford. Dr. Dzau's academic interests are in cardiovascular translational research and mission-based education. His laboratory has studied the molecular and genetic mechanisms of cardiovascular disease and applied genomic and gene transfer technologies to develop novel therapeutic approaches. His work on the renin angiotensin system (RAS) paved the way for the contemporary understanding of RAS in cardiovascular disease and the development of RAS inhibitors (e.g. ACE inhibitor) as therapeutics. He pioneered gene therapy for vascular disease, being the first to introduce DNA decoy molecules to block transcriptions as gene therapy in vivo. Two of his discoveries E2F decoy and nitric oxide synthase gene therapy are now being evaluated in clinical trials.

Art Pappas, Managing Partner, Pappas Ventures

* Art Pappas has over 30 years of experience as a pharmaceutical and biotechnology industry executive and venture capital investor in life science companies. Prior to founding Pappas Ventures in 1994, he held senior level positions at several multinational pharmaceutical companies. He was an executive member of the board of directors of Glaxo Holdings plc, for which he was responsible for international operations including research, development and manufacturing. Pappass previously was Vice President of Commercial Operations for Abbott International Ltd., and he held various executive positions with Merrell Dow Pharmaceuticals and the Dow Chemical Company, in the United States and internationally. Among the companies for which he currently serves as a director are: AtheroGenics (Nasdaq: AGIX), which conducted a successful IPO in 2000, BrainCells, Genstruct, and Syntonix Pharmaceuticals. He is chairman of CoLucid Pharmaceuticals. Art previously served as a board observer at Variagenics (Nasdaq: NUVO), which completed a successful IPO in 2000, and he was directly responsible for investments in Gene Logic (Nasdaq: GLGC), which went public in 1997, and Novalon Pharmaceutical, which was acquired at a substantial premium by a publicly held Swedish company. He also previously served on the boards of Embrex (Nasdaq: EMBX), Quintiles Transnational and Valentis (Nasdaq: VLTS).

Dan Pelino, General Manager, IBM Healthcare and Life Sciences Industry

* Dan Pelino leads a team developing the latest information technology solutions and services, establishing partnerships, and overseeing IBM investments in the healthcare, pharmaceutical and life sciences markets. He works closely with leaders in healthcare and life sciences, including public and private healthcare providers and payers, and biotech and pharmaceutical companies, to help them leverage IBM capabilities to innovate and grow. During his career, he has held several positions in marketing and sales. He is involved in many organizations, including the Advisory Board of Western Kentucky University, Chicagoland Chamber of Commerce, Illinois Governor's Transition Team Streamlining Government Committee, the Board of Directors for Teach for America. Dan received a Masters Degree in Organizational Communications and a Bachelor of Science undergraduate degree in Business Administration and Public Relations from Western Kentucky University.

John Ratliff, Executive Vice President and Chief Financial Officer, Quintiles Transnational Corp.

* John Ratliff came to Quintiles Transnational in 2004 as Chief Financial Officer. As Chairman of the Financial Operations subcommittee of the Executive Committee, Ratliff brings to his role a strong financial background and experience with large multinational companies. Prior to joining Quintiles, Ratliff worked for Acterna, the world's second largest provider of communications test solutions for telecommunications and cable network operators. Before moving to Acterna in 2000, he worked 19 years at IBM, holding several positions of increasing responsibility. Ratliff's most recent positions at IBM included Vice President for Finance and Planning, Latin America, Vice President for Finance and Planning, PC Company, and Assistant Controller. Ratliff received his bachelor's degree in industrial and systems engineering from the Georgia Institute of Technology in Atlanta and his MBA from Duke University